Indegene is a life-sciences focused digital and AI services provider whose Q2 FY27 print will test whether its margin recovery story stays on track after Q1 FY27 revenue grew 39.7% YoY to Rs. 10,631 Mn. The two big things to watch are the EBITDA margin trajectory — management has guided 19%-20% by Q4 FY27 with an 'inflection point in Q3 FY27' — and the first revenue contribution from the $10 Mn+ top-10 pharma omnichannel deal slated to start this quarter.
| Results date | October 29, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 10,631 Mn |
| Previous quarter PAT | Rs. 1,162 Mn |
| Previous quarter EBITDA margin | 16.9% |
| Market cap | Rs. 13,778.48 Cr |
| CMP | Rs. 571.9 |
The board meeting is scheduled for 29 Oct 2026 to consider the Q2/H1 FY27 results (along with RSU/ESOP allotments), per the 30 Sep 2026 intimation. The trading window has been closed from 1 Oct 2026 until 48 hours after the results.
The Q2 FY27 earnings call is scheduled for 30 Oct 2026 at 8:00 AM IST. Speakers are Manish Gupta (Chairman & CEO) and Suhas Prabhu (CFO).
The quarter's central question is whether Indegene can hold its sequential EBITDA improvement — Q1 FY27 delivered +8.9% QoQ EBITDA growth and a 16.9% reported margin, up 50 bps QoQ — against the 1 Jul 2026 wage-hike cycle, the same seasonal drag that cost about 2.1% of sequential margin in Q2 FY26. Management has repeatedly guided consolidated EBITDA margins back to the 19%-20% band by Q4 FY27/H2 FY27, with an 'inflection point in Q3 FY27', and stated that 'nothing we have seen in this quarter changes that expectation'. On growth, the pipeline entering FY27 was 17% higher than the prior year, and the Q3 FY26 top-10 pharma omnichannel orchestration deal is slated to yield $10 Mn+ annual revenues starting Q2 FY27; Q1 FY27 also saw USD revenue grow 2.5% QoQ, the highest sequential USD growth in four years. A modestly weaker average rupee over July-September adds an INR translation tailwind for the 84-85% of revenues that are USD-billed, while the enjoined $100,000 H-1B fee means no new direct visa-cost shock in the window. The TCPA class settlement — Rs. 203 Mn provisioned against a USD 4.72 Mn maximum fund — has preliminary court approval as of 27 Aug 2026, with the claim deadline on 9 Dec 2026 and the final approval hearing on 12 Jan 2027. The call is also likely to cover the ECS segment margin path toward the guided level above 20% by Q4 FY27, after a Q1 FY27 segment result of Rs. 1,197 Mn on Rs. 7,502 Mn revenue.
EBITDA margin vs the 19%-20% guidance: Margin recovery is the dominant swing factor for this call.
Large-deal ramp and pipeline conversion: Revenue evidence of the deals management has already signed.
ECS segment margin trajectory: The segment margin path toward the guided target.
TCPA settlement and board transition: Legal and governance items with dated milestones.
BioPharm synergies, capex and client pyramid goals: Strategic and structural updates to track.
Management has guided consolidated EBITDA margins back to the 19%-20% band by Q4 FY27/H2 FY27, describing Q3 FY27 as the 'inflection point'. Q1 FY27's reported margin was 16.9%, up 50 bps QoQ.
Management has attributed the compression to go-to-market investments made 'ahead of the curve' and carried costs of contracted Tectonic and GenAI engagements where revenue contribution is still building. Q1 FY27's 16.9% margin remained 330 bps below Q1 FY26's 20.2%.
Management has pointed to deep domain expertise, proprietary data, and the required 'human-in-the-loop' for regulatory compliance as its defense. The company also spends slightly above 2% of revenue on R&D.
No — management has stated, 'We're not breaking up organic and inorganic growth from a BioPharm perspective, anymore'. Q1 FY27 USD growth of 2.5% QoQ translates to roughly 2.6%-2.7% constant currency, with 84-85% of revenues in USD.
The settlement received preliminary court approval from the US District Court (New Jersey) on 27 Aug 2026, with a maximum fund of USD 4.72 Mn against a Rs. 203 Mn provision already recognized. The claim deadline is 9 Dec 2026 and the final approval hearing is on 12 Jan 2027.